ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.
May 29, 2020 – ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors
May 18, 2020 – ALX Oncology to Present ALX148 Phase 1 Clinical Data at the Virtual 25th Congress of the European Hematology Association (EHA)
May 14, 2020 – ALX Oncology to Present ALX148 Phase 1 Study at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting